Strategic partnerships TG Therapeutics operates as a fully integrated commercial-stage biotechnology company with FDA approvals for therapies targeting B-cell diseases and multiple sclerosis, presenting opportunities for co-development, licensing, or distribution partnerships with larger pharma players seeking to expand CNS and autoimmune portfolios.

Financial growth With annual revenue in the mid hundreds of millions and a recent $750 million senior secured credit facility, TG Therapeutics demonstrates strong funding and liquidity, suggesting capacity for expanded clinical programs, pipeline investments, or strategic acquisitions that could broaden market reach.

Pipeline expansion Licensing of azer-cel in autoimmune diseases worldwide signals active pipeline leveraging, offering sales teams entry points into novel autoimmune indications beyond oncology, creating cross-sell potential with existing B-cell therapy expertise.

Investor and conference cadence Active engagement with major investor conferences and leadership appearances indicate a visibility strategy to attract partners and funders, providing avenues for targeted outreach around collaboration opportunities, co-funding strategies, and strategic alliances.

Global regulatory footprint FDA-approved therapies plus regulatory approvals outside the U.S. underscore a multinational regulatory experience and established commercialization capability, enabling BD outreach for international distribution deals, market access collaborations, and supply chain partnerships.